相关实验视频
Updated: Jul 15, 2025

08:48
Author Spotlight: Decoding Mitochondrial Aging
Published on: June 30, 2023
4.0K
线粒体向干预在阿尔茨海默氏病的当前进展
Tiago Sousa1, Paula I Moreira2,3,4, Susana Cardoso2,3,5
1Faculty of Medicine, University of Coimbra, 3000-370 Coimbra, Portugal.
Biomedicines
|September 28, 2023
概括
缺少阿尔茨海默病 (AD) 的治疗方法. 本综述强调了阿尔茨海默病中的线粒体功能障碍,并探讨了针对线粒体的治疗策略,以进行早期干预.
科学领域:
- 神经退行性疾病 神经退行性疾病
- 细胞生物学 细胞生物学
- 线粒体医学 线粒体医学
背景情况:
- 阿尔茨海默病 (AD) 是神经退行的主要原因,影响患者和护理人员.
- 目前对阿尔茨海默病的治疗方法是无效的,部分原因是晚期诊断.
- 早期发现和干预对于开发有效的AD疗法至关重要.
研究的目的:
- 审查阿尔茨海默病中线粒体功能障碍的证据.
- 探索针对AD中线粒体的新型治疗策略.
主要方法:
- 关于AD中线粒体功能障碍的先前和最近研究的文献综述.
- 针对线粒体的治疗策略的分析.
主要成果:
- 与非AD个体相比,AD患者和模型中的线粒体表现出功能障碍.
- 线粒体健康和功能是AD治疗的有希望的目标.
结论:
- 针对线粒体功能障碍是开发阿尔茨海默病早期干预措施的关键策略.
- 对线粒体集中治疗的进一步研究可能会导致对AD的有效治疗方法.
更多相关视频
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
529
11:47Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
Published on: January 22, 2017
10.6K
相关概念视频
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Electron Transport Chain: Complex I and II
14.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.3K
Mitochondria
13.7K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
13.7K